Waldencast announces conclusion of SEC investigation
Rhea-AI Summary
Waldencast (NASDAQ: WALD) announced on April 28, 2026 that the SEC has concluded its investigation related to Waldencast's restatement and historical accounting practices at Obagi Cosmeceuticals.
Based on available information, the SEC does not intend to recommend enforcement action. The company said it fully cooperated and incurred substantial legal and advisory costs.
Positive
- SEC does not intend to recommend enforcement action
- Company fully cooperated with the SEC investigation
Negative
- Company previously restated financial results and identified material weaknesses
- Incurring substantial legal, advisory and related costs
Market Reaction – WALD
Following this news, WALD has gained 39.71%, reflecting a significant positive market reaction. The stock is currently trading at $1.09. This price movement has added approximately $28M to the company's valuation. Trading volume is exceptionally heavy at 6.5x the average, suggesting very strong buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Market Reality Check
Peers on Argus
WALD gained 1.18% while momentum peers were mixed: SKIN up 5.16% and DSY down 3.02%. Broader peers showed small, mostly negative moves, suggesting today’s SEC resolution is stock-specific rather than a sector-wide driver.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 24 | Product launch | Positive | -7.4% | Launch of NU-GEN Cellular Renewal Serum with strong clinical skincare claims. |
| Mar 19 | Clinical collaboration | Positive | -8.3% | Collaboration with ProMD in ALOHA Program to build real-world evidence. |
| Mar 13 | Earnings results | Positive | +8.2% | Q4/FY25 results with $272.1M revenue, positive EBITDA and lower net debt. |
| Mar 11 | Earnings timing | Negative | -4.0% | Announcement of earnings date and no conference call amid strategic review. |
| Feb 27 | Phase 4 program | Positive | -0.6% | Phase 4 and real-world ALOHA study for Obagi saypha MagIQ with partner clinic. |
Recent product and collaboration news for Obagi often coincided with negative price reactions, while the latest earnings report saw a positive move, indicating selective investor focus on financials over operational updates.
Over the past months, Waldencast has balanced brand initiatives with financial restructuring. On Feb 27, Obagi collaborations and a Phase 4 study generated limited share response. An earnings-date 6-K on Mar 11 and the decision not to host a call preceded Q4/FY25 results on Mar 13, when revenue of $272.1M and reduced net debt drove an 8.22% gain. Subsequent Obagi product and ALOHA collaboration news in March saw share declines, making today’s closure of the SEC investigation a notable governance milestone against a backdrop of mixed reactions.
Market Pulse Summary
This announcement removes the uncertainty of an SEC investigation into Waldencast’s restatement and control weaknesses, with staff indicating no intent to recommend enforcement. It follows a period of strategic activity, including FY25 revenue of $272.1M and balance sheet refinancing, while the stock trades close to its 52-week low and below the 200-day MA. Investors may watch future filings, internal control disclosures, and brand performance at Obagi and Milk for confirmation that governance and financial reporting remain on solid footing.
Key Terms
u.s. securities and exchange commission regulatory
internal control over financial reporting financial
AI-generated analysis. Not financial advice.
LONDON, April 28, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, announced today that it was notified by the staff of the U.S. Securities and Exchange Commission (the “SEC”) that they have concluded their investigation of the Company relating to Waldencast’s restatement of its financial results and material weaknesses in its internal control over financial reporting related to historical accounting practices used by Obagi Cosmeceuticals (the “Investigation”) and, based on the information available as of the date of the notice, the SEC does not intend to recommend an enforcement action against Waldencast.
“We are pleased with the favorable outcome of the SEC’s investigation,” stated Michel Brousset, Chief Executive Officer of Waldencast. “Throughout the Investigation, we fully cooperated and dedicated significant resources to the process. At the same time, we maintained our focus on executing our business plans, upholding strong governance, and ensuring robust internal controls.”
The Investigation was previously disclosed by the Company in its periodic reports under the Securities Exchange Act of 1934, as amended. As previously disclosed, the Company voluntarily contacted the SEC regarding these matters and has fully cooperated with the SEC throughout the course of the Investigation, incurring substantial legal, advisory and other related costs.
About Waldencast plc
Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. For more information please visit: https://ir.waldencast.com.
Obagi Medical is an industry-leading, advanced skin care line rooted in research and skin biology, refined with a legacy of over 35 years’ experience. Obagi Medical products are designed to address the appearance of premature aging, photodamage, skin discoloration, acne, and sun damage. More information about Obagi Medical is available on the brand’s website at www.obagi.com.
Founded in 2016, Milk Makeup quickly became a cult-favorite among the beauty community for its values of self-expression and inclusion, captured by its signature “Live Your Look”, its innovative formulas, and clean ingredients. The brand creates vegan, cruelty-free, clean formulas and has its Milk Makeup HQ in Downtown NYC. More information about Milk Makeup is available on the brand’s website at www.milkmakeup.com.
Contacts:
Investors
ICR
Allison Malkin
waldencastir@icrinc.com
Media
ICR
Brittney Fraser/Alecia Pulman
waldencast@icrinc.com
